Oncology Clinical Trials Market Set for Strong Growth Through 2035, Fueled by Precision Medicine, Immunotherapy and Decentralized Trial Innovation

Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Oncology Clinical Trials Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

The global oncology clinical trials market is projected to expand from approximately USD 14.95 billion in 2025 to USD 25.61 billion by 2035, registering a compound annual growth rate of 5.53% from 2026 to 2035. Rising cancer incidence, sustained pharmaceutical research investment, and demand for innovative cancer treatments are supporting the continued expansion of oncology drug development programs worldwide.

Aging populations, environmental exposure, and lifestyle-related risk factors are contributing to a growing global cancer burden. In response, pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions are increasing investment in oncology clinical trials. These initiatives are intended to accelerate the evaluation and regulatory approval of targeted therapies, immunotherapies, antibody-drug conjugates, and other advanced treatment modalities.

Competitive Landscape and Market Developments

Competition within the oncology clinical trials market remains intense, with strategic partnerships, licensing agreements, and industry consolidation shaping the research pipeline. AstraZeneca, Merck & Co., Roche, and Novartis collectively controlled approximately 35% of the oncology clinical trial pipeline in 2025, reflecting the significant role of large pharmaceutical companies in global cancer research.

AstraZeneca has strengthened its position in the antibody-drug conjugate segment through the clinical performance of Enhertu across multiple cancer indications. Progress in this area is influencing oncology research priorities and increasing competition among companies seeking to develop differentiated therapies for cancers with substantial unmet medical needs.

Key Oncology Clinical Trials Market Growth Drivers

The rising incidence of cancer is a primary growth driver for the global oncology clinical trials market. Healthcare systems face increasing pressure to improve survival rates, expand treatment options, and address difficult-to-treat malignancies. Pharmaceutical sponsors and research organizations are consequently broadening clinical development programs and conducting multinational studies to support faster patient access to advanced therapies.

Artificial intelligence is also creating new opportunities across oncology clinical research. AI-enabled platforms are being applied to patient identification, recruitment planning, protocol optimization, site selection, and clinical data analysis. Greater use of these technologies may improve trial efficiency, strengthen decision-making, and reduce avoidable delays across the development lifecycle.

Patient recruitment remains a significant operational barrier. Historically, fewer than 5% of adult cancer patients have participated in clinical trials. Limited enrollment can delay study completion, increase development costs, and restrict access to representative patient populations. Sponsors are responding with decentralized research capabilities, data-driven recruitment strategies, broader site networks, and patient-focused trial designs.

Oncology Clinical Trials Market Segmentation

By phase, Phase III trials represent more than 48.89% of the total market. Their leading position reflects the scale, duration, and cost of multinational studies conducted to generate confirmatory safety and efficacy data before regulatory review.

By study design, interventional studies account for more than 71% of the market. Their dominance is supported by extensive investment in investigational oncology therapies and the substantial requirements associated with protocol execution, regulatory compliance, site coordination, and patient monitoring.

Market Segments by Phase

Market Segments by Study Design

Regional Market Coverage

North America Maintains a Leading Research Position

North America remains a leading region in the global oncology clinical trials market, supported by major pharmaceutical and biotechnology companies, advanced medical institutions, established research networks, and a supportive regulatory environment. The region accounted for more than 58% of radiation oncology studies as of early 2024, demonstrating its capacity to conduct specialized and complex cancer research.

The number of registered clinical studies in North America increased from 477,200 in 2023 to approximately 520,874 by late 2024. Of these, 68,453 trials focused on cancer-related interventions. This concentration reinforces the region's importance in oncology innovation, although Europe and Asia Pacific continue to gain prominence through expanding research infrastructure, broader patient populations, and increased industry investment.

Leading Oncology Clinical Trials Market Participants

The outlook for the oncology clinical trials market remains positive as precision medicine, biomarker-led research, artificial intelligence, and international trial networks reshape cancer drug development. Continued collaboration among pharmaceutical companies, research institutions, clinical service providers, regulators, and patient communities will be essential to improve enrollment, streamline trial execution, and bring innovative oncology treatments to patients more efficiently.

Key Attributes:

Key Topics Covered:

Chapter 1. Executive Summary: Global Oncology Clinical Trials Market

Chapter 2. Report Description

2.1. Research Framework

2.1.1. Research Objective

2.1.2. Market Definitions

2.1.3. Market Segmentation

2.2. Research Methodology

2.2.1. Market Size Estimation

2.2.2. Qualitative Research

2.2.2.1. Primary & Secondary Sources

2.2.3. Quantitative Research

2.2.3.1. Primary & Secondary Sources

2.2.4. Breakdown of Primary Research Respondents, By Region

2.2.5. Data Triangulation

2.2.6. Assumption for Study

Chapter 3. Global Oncology Clinical Trials Market Overview

3.1. Industry Value Chain Analysis

3.1.1. Drug Discovery & Preclinical Development

3.1.2. Clinical Trial Planning & Regulatory Approval

3.1.3. Clinical Trial Execution & Patient Recruitment

3.1.4. Clinical Trial Supply & Logistics

3.1.5. Data Analysis & Regulatory Submission

3.1.6. Commercialization

3.2. Industry Outlook

3.2.1. Growing Oncology Drug Pipeline

3.2.2. Increasing Cancer Incidence Globally

3.2.3. Rising Outsourcing to CROs

3.2.4. Increasing Adoption of Precision Medicine

3.2.5. Regulatory Support for Oncology Trials

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitutes

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Growth and Outlook

3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035

3.5.2. Pricing Analysis, By Phase Type

3.6. Market Attractiveness Analysis

3.6.1. By Phase Type

3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate

4.2. Company Market Share Analysis (Value %), 2025

4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Oncology Clinical Trials Market Analysis

5.1. Market Dynamics and Trends

5.1.1. Growth Drivers

5.1.2. Restraints

5.1.3. Opportunity

5.1.4. Key Trends

5.2. Market Size and Forecast, 2020-2035 (US$ Mn)

5.2.1. By Phase Type

5.2.1.1. Key Insights

5.2.1.1.1. Phase I

5.2.1.1.2. Phase II

5.2.1.1.3. Phase III

5.2.1.1.4. Phase IV

5.2.2. By Study Design

5.2.2.1. Key Insights

5.2.2.1.1. Interventional Studies

5.2.2.1.2. Observational Studies

5.2.2.1.3. Expanded Access Studies

5.2.3. By Region

5.2.3.1. Key Insights

5.2.3.1.1. North America

5.2.3.1.1.1. The U.S.

5.2.3.1.1.2. Canada

5.2.3.1.1.3. Mexico

5.2.3.1.2. Europe

5.2.3.1.2.1. Western Europe

5.2.3.1.2.1.1. The UK

5.2.3.1.2.1.2. Germany

5.2.3.1.2.1.3. France

5.2.3.1.2.1.4. Italy

5.2.3.1.2.1.5. Spain

5.2.3.1.2.1.6. Rest of Western Europe

5.2.3.1.2.2. Eastern Europe

5.2.3.1.2.2.1. Poland

5.2.3.1.2.2.2. Russia

5.2.3.1.2.2.3. Rest of Eastern Europe

5.2.3.1.3. Asia Pacific

5.2.3.1.3.1. China

5.2.3.1.3.2. India

5.2.3.1.3.3. Japan

5.2.3.1.3.4. South Korea

5.2.3.1.3.5. Australia & New Zealand

5.2.3.1.3.6. ASEAN

5.2.3.1.3.6.1. Indonesia

5.2.3.1.3.6.2. Malaysia

5.2.3.1.3.6.3. Thailand

5.2.3.1.3.6.4. Singapore

5.2.3.1.3.6.5. Rest of ASEAN

5.2.3.1.3.7. Rest of Asia Pacific

5.2.3.1.4. Middle East & Africa

5.2.3.1.4.1. UAE

5.2.3.1.4.2. Saudi Arabia

5.2.3.1.4.3. South Africa

5.2.3.1.4.4. Rest of MEA

5.2.3.1.5. South America

5.2.3.1.5.1. Argentina

5.2.3.1.5.2. Brazil

5.2.3.1.5.3. Rest of South America

Chapter 6. North America Oncology Clinical Trials Market Analysis

6.1. Market Dynamics and Trends

6.1.1. Growth Drivers

6.1.2. Restraints

6.1.3. Opportunity

6.1.4. Key Trends

6.2. Market Size and Forecast, 2020-2035 (US$ Mn)

6.2.1. By Phase Type

6.2.2. By Study Design

6.2.3. By Country

Chapter 7. Europe Oncology Clinical Trials Market Analysis

7.1. Market Dynamics and Trends

7.1.1. Growth Drivers

7.1.2. Restraints

7.1.3. Opportunity

7.1.4. Key Trends

7.2. Market Size and Forecast, 2020-2035 (US$ Mn)

7.2.1. By Phase Type

7.2.2. By Study Design

7.2.3. By Country

Chapter 8. Asia Pacific Oncology Clinical Trials Market Analysis

8.1. Market Dynamics and Trends

8.1.1. Growth Drivers

8.1.2. Restraints

8.1.3. Opportunity

8.1.4. Key Trends

8.2. Market Size and Forecast, 2020-2035 (US$ Mn)

8.2.1. By Phase Type

8.2.2. By Study Design

8.2.3. By Country

Chapter 9. Middle East & Africa Oncology Clinical Trials Market Analysis

9.1. Market Dynamics and Trends

9.1.1. Growth Drivers

9.1.2. Restraints

9.1.3. Opportunity

9.1.4. Key Trends

9.2. Market Size and Forecast, 2020-2035 (US$ Mn)

9.2.1. By Phase Type

9.2.2. By Study Design

9.2.3. By Country

Chapter 10. South America Oncology Clinical Trials Market Analysis

10.1. Market Dynamics and Trends

10.1.1. Growth Drivers

10.1.2. Restraints

10.1.3. Opportunity

10.1.4. Key Trends

10.2. Market Size and Forecast, 2020-2035 (US$ Mn)

10.2.1. By Phase Type

10.2.2. By Study Design

10.2.3. By Country

Chapter 11. Company Profiles (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

11.1. AbbVie Inc.

11.2. AstraZeneca PLC

11.3. BeiGene Ltd.

11.4. Bristol Myers Squibb

11.5. Charles River Laboratories

11.6. Clovis Oncology

11.7. Eli Lilly and Company

11.8. F. Hoffmann-La Roche Ltd

11.9. IQVIA

11.10. ICON plc

11.11. Johnson & Johnson

11.12. Labcorp Drug Development

11.13. Medpace Holdings

11.14. Merck & Co., Inc.

11.15. Novartis AG

11.16. Parexel International

11.17. Pfizer Inc.

11.18. Syneos Health

11.19. Takeda Pharmaceutical

11.20. Thermo Fisher Scientific

11.21. Wuxi Clinical CRO

11.22. Other Prominent Players

Chapter 12. Annexure

12.1. List of Secondary Sources

12.2. Key Country Markets - Macro Economic Outlook/Indicators

For more information about this report visit https://www.researchandmarkets.com/r/2yljqs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.